Relmada Therapeutics, Inc. (RLMD) News
Filter RLMD News Items
RLMD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest RLMD News From Around the Web
Below are the latest news stories about RELMADA THERAPEUTICS INC that investors may wish to consider to help them evaluate RLMD as an investment opportunity.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call TranscriptRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call Transcript November 9, 2023 Relmada Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.73, expectations were $-0.95. Operator: Good afternoon, ladies and gentlemen. And welcome to Relmada Therapeutics, Inc. Third Quarter 2023 Earnings Conference Call. At this time, all lines are in listen-only mode. Following the presentation, […] |
Relmada Therapeutics Inc (RLMD) Reports Third Quarter 2023 Financial ResultsProgress in Clinical Development and Financial Highlights |
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsRelmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the third quarter ended September 30, 2023. The Company will host a conference call today, Wednesday, November 8, at 4:30 PM Eastern Time/1:30 PM Pacific Time. |
Positive Signs As Multiple Insiders Buy Relmada Therapeutics StockGenerally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying... |
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2023 after the market close on Wednesday, November 8, 2023. The company will host a corporate update conference call and live audio webcast at 4:30 p.m. Eastern Time on Wednesday, November 8, 2023. |
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that new preclinical data on its novel psilocybin will be highlighted in a poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2023, being held November 10-14, 2023, in Boston, MA. |
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro SummitRelmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, Maged Shenouda, Chief Financial Officer, and Cedric O'Gorman, Chief Medical Officer, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit in one-on-one investor meetings and a fireside chat on Thursday, October 12, 2023, at 2:30pm ET in New York, NY. Please find additional details abou |
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) CongressRelmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will present three posters at the upcoming 36th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 7-10, 2023, in Barcelona, Spain. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday. |
Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although... |